Pfizer signs global licensing deal with 3SBio for bispecific antibody
Pfizer will pay $1.25 upfront, and 3SBio could earn up to $4.8bn in milestone payments.

Pfizer will pay $1.25 upfront, and 3SBio could earn up to $4.8bn in milestone payments.
AI is now used throughout clinical trials, from recruitment to analysis – but are regulators keeping up?
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Recursion axes drug programmes to streamline pipeline
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal
3 reasons why biotechs preparing for launch need a compliant content foundation